The FASEB Journal, Vol 4, 3251-3255, Copyright © 1990 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Protection against cisplatin toxicity by administration of glutathione ester

ME Anderson, A Naganuma and A Meister
Department of Biochemistry, Cornell University Medical College, New York, New York 10021.

The role of cellular glutathione in the prevention of toxicity due to the anti-cancer drug cisplatin (cis-diamminedichloroplatinum) was explored in mice treated with buthionine sulfoximine (BSO), a selective inhibitor of gamma-glutamylcysteine synthetase (and therefore of glutathione synthesis), and with glutathione and glutathione monoisopropyl ester. Pretreatment of mice with BSO enhanced the lethal toxicity of cisplatin by about twofold. Administration of glutathione ester (dose, 2.5-7.5 mmol/kg) protected against lethal cisplatin toxicity; glutathione was also effective, but much less so. Glutathione ester, in contrast to glutathione, is effectively transported into cells and split to glutathione intracellularly. The previous findings that administered glutathione does not protect against lethal toxicity due to cadmium ions and mercuric ions, whereas glutathione ester does, suggest that intracellular glutathione is required for protection against these heavy metal ions. That administration of glutathione has a protective effect on cisplatin toxicity suggests that the toxic effects of cisplatin may be exerted both intracellularly and extracellularly, and that extracellular glutathione (or its degradation products) may form a complex with cisplatin extracellularly. The finding that glutathione ester is more effective than glutathione in protecting against the toxicity of cisplatin suggests that use of glutathione ester may be therapeutically advantageous.

This article has been cited by other articles:

				D. Sheikh-Hamad Cisplatin-induced cytoxicity: is the nucleus relevant? Am J Physiol Renal Physiol, July 1, 2008; 295(1): F42 - F43. [Full Text] [PDF]

				H. Hentze, I. Schmitz, M. Latta, A. Krueger, P. H. Krammer, and A. Wendel Glutathione Dependence of Caspase-8 Activation at the Death-inducing Signaling Complex J. Biol. Chem., February 8, 2002; 277(7): 5588 - 5595. [Abstract] [Full Text] [PDF]

				L. L. Muldoon, S. L. Walker-Rosenfeld, C. Hale, S. E. Purcell, L. C. Bennett, and E. A. Neuwelt Rescue from Enhanced Alkylator-Induced Cell Death with Low Molecular Weight Sulfur-Containing Chemoprotectants J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 797 - 805. [Abstract] [Full Text]

				C. R Jonas, A. B Puckett, D. P Jones, D. P Griffith, E. E Szeszycki, G. F Bergman, C. E Furr, C. Tyre, J. L Carlson, J. R Galloway, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients Am. J. Clinical Nutrition, July 1, 2000; 72(1): 181 - 189. [Abstract] [Full Text] [PDF]

				E. A. Neuwelt, R. E. Brummett, N. D. Doolittle, L. L. Muldoon, R. A. Kroll, M. A. Pagel, R. Dojan, V. Church, L. G. Remsen, and J. S. Bubalo First Evidence of Otoprotection Against Carboplatin-Induced Hearing Loss with a Two-Compartment System in Patients with Central Nervous System Malignancy Using Sodium Thiosulfate J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 77 - 84. [Abstract] [Full Text]

				T. W. Prewitt, W. Matthews, G. Chaudhri, H. W. Pogrebniak, and H. I. Pass Tumor necrosis factor induces doxorubicin resistance to lung cancer cells in vitro J. Thorac. Cardiovasc. Surg., January 1, 1994; 107(1): 43 - 49. [Abstract] [Full Text]